One study has shown that the hypermethylation status of CST6 promoter resulted in CST6 deficiency in glioma tumor-initiating cells, while the promoter was hypomethylated in normal brain tissues (Qiu et al., 2008). Here, CST6 is linked to central nervous system cancer.